Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
43 hedge funds and large institutions have $71.7M invested in Cellular Biomedicine Group, Inc. in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 0 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
14% more capital invested
Capital invested by funds: $63.1M → $71.7M (+$8.68M)
8% more funds holding
Funds holding: 40 → 43 (+3)
37% less call options, than puts
Call options by funds: $201K | Put options by funds: $317K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.04M |
| 2 |
BlackRock
New York
|
+$546K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$355K |
| 4 |
Two Sigma Investments
New York
|
+$350K |
| 5 |
JP Morgan Chase
New York
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$416K |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$416K |
| 3 |
Barclays
London,
United Kingdom
|
-$99.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$34.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17.9K |
CBMG Hedge Fund Activity: Q4 2019 in Review
43 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2019, worth a combined $71.7M — up 14% from $63.1M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CBMG positions and 0 closed out — a net gain of 3 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $1.04M. The largest seller was Nikko Asset Management Americas, cutting an estimated $416K.
- 43 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2019, up from 40 in Q3 2019.
- Funds reported $71.7M of Cellular Biomedicine Group, Inc. stock for Q4 2019, up 14% quarter-over-quarter.
- 3 funds opened new Cellular Biomedicine Group, Inc. positions in Q4 2019 and 0 closed out, a net change of +3 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q4 2019 was ARK Investment Management, an estimated $1.04M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q4 2019 was Nikko Asset Management Americas, an estimated $416K sold.
Based on aggregated 13F filings for Q4 2019.